Table 1. Clinical Data of Patients (N) After Orthotropic Liver Transplantation.
| Patients | Mean ± SD | Median | |
|---|---|---|---|
| Gender, No. (%) | |||
| Female | 59 (46.1) | - | - |
| Male | 69 (53.9) | - | - |
| Age, y, range | 24-70 | 50.22 ± 11.1 | 52 |
| Body mass index, kg/m2, range | 16.7-35.6 | 25.2 ± 4.4 | 24.5 |
| Split liver, No. (%) | 18 (14.1) | ||
| Graft size, kg, range | 0.7-2.9 | 1.6 ± 0.4 | 1.6 |
| Duct to duct anastomosis | 103 (80.5) | ||
| Biliodigestive anastomosis | 25 (19.5) | ||
| Stenting therapy, No. (%) | 24 (18.8) | 12 ± 8.6 | 10.5 |
| Duration of stenting therapy, mo, range | 0-38 | 12 ± 8.6 | 10.5 |
| Death | 17 (13.3) | 17 (13.3) | |
| Biliary Complications on Cholangiography (ERC/PTC) | |||
| Within 3 months | 20 (47.6) | ||
| Within 1 year | 17 (40.5) | ||
| After 1 year | 5 (11.9) | ||
| Other imaging modalities | |||
| CT | 16 (38.1) | ||
| MRCP | 3 (7.1) | ||
| CT and MRCP | 9 (21.4) | ||
| Liver disease | |||
| Chronic viral hepatitis | 31 (24.2) | ||
| Alcoholic | 24 (18.8) | ||
| Primary sclerosing cholangi | 23 (18) | ||
| Others a | 20 (15.6) | ||
| Autoimmune b | 12 (9.4) | ||
| Unknown | 8 (6.3) | ||
| Cystic | 6 (4.7) | ||
| Acute liver failure | 4 (3.1) | ||
| Additional tumor c | 29 (22.7) | ||
Abbreviations: CT, computed topography, MRCP, Magnetic resonance Cholangio Pancreatography
aOthers include: Hepatocellular carcinoma, oxalises, cystic fibrosis, secondary sclerosing cholangitis, Amyloidosis, carcinoid disease, alpha1 antitrypsin deficiency, glycogenesis, non-alcoholic steatohepatitis, glycogenesis, familiar hypercholesterolemia, Budd chiari syndrome
bAutoimmune includes: Autoimmune hepatitis and primary biliary cirrhosis
cn = 3 cholangiocellular carcinoma, n = 26 hepatocellular carcinomas